Abnormal expression of ABCD3 is an independent prognostic factor for colorectal cancer

Zhang,Yujiao; Zhang,Yaqi; Wang,Jiping; Yang,Jiyuan; Yang,Guodong

doi:10.3892/ol.2020.11463

Abnormal expression of ABCD3 is an independent prognostic factor for colorectal cancer

Authors:
- Yujiao Zhang
- Yaqi Zhang
- Jiping Wang
- Jiyuan Yang
- Guodong Yang
View Affiliations

Affiliations: Department of Respiratory Medicine, Huanggang Central Hospital Affiliated to Yangtze University, Huanggang, Hubei 438000, P.R. China, Department of Oncology, Huanggang Central Hospital Affiliated to Yangtze University, Huanggang, Hubei 438000, P.R. China, Department of Radiotherapy, Huanggang Central Hospital Affiliated to Yangtze University, Huanggang, Hubei 438000, P.R. China, Department of Oncology, The First People's Hospital Affiliated to Yangtze University, Jingzhou, Hubei 434000, P.R. China
Published online on: March 16, 2020 https://doi.org/10.3892/ol.2020.11463
Pages: 3567-3577
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

ATP binding cassette subfamily D member 3 (ABCD3) is a member of the superfamily of ATP-binding cassette (ABC) transporters, which serve crucial roles in the process of tumor cell resistance to chemotherapy. The present study investigated the diagnostic and prognostic capabilities of ABCD3 in colorectal cancer (CRC) by bioinformatics analysis. Gene expression data and corresponding clinical information of patients with CRC were collected from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The results demonstrated that ABCD3 mRNA level was decreased in CRC tissues compared with normal tissues following Wilcoxon test analysis. Furthermore, ABCD3 protein expression was significantly higher in normal colon tissues compared with colon adenocarcinoma tissues according to the Human Protein Atlas. In addition, the area under the Receiver Operating Characteristic curve based on comparison between the tumor and normal groups derived from TCGA and GEO databases demonstrated that the use of ABCD3 mRNA level may be used for the diagnosis of CRC. ABCD3 expression was significantly associated with clinical stage, T stage, and lymph node status following Kruskal‑Wallis test or Wilcoxon rank sum test, logistic regression and χ2 test. Furthermore, the results from Kaplan‑Meier survival analysis indicated that low ABCD3 mRNA expression had a poorer prognosis value compared with ABCD3 high expression in patients with CRC. In addition, results from univariate Cox regression analysis indicated that ABCD3 mRNA expression was associated with overall survival (OS), and results from multivariate Cox analysis indicated that ABCD3 mRNA expression may be considered an independent prognostic factor from other clinical factors, such as clinical stage, sex and age. The results from Gene Set Enrichment Analysis demonstrated that the ABCD3 high‑expression phenotype was differentially enriched in five biological processes, including apoptosis, cell cycle, renal cell carcinoma, thyroid cancer and colorectal cancer. The findings from this study demonstrated that ABCD3 mRNA expression may be considered as a potential diagnostic and prognostic biomarker in patients with CRC. ABCD3 expression levels may participate in the regulation of cell apoptosis and cell cycle. In addition, GSEA analysis identified Kyoto Encyclopaedia of Genes and Genomes pathways for renal cell carcinoma, thyroid cancer and CRC involving ABCD3.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Landreau P, Drouillard A, Launoy G, Ortega-Deballon P, Jooste V, Lepage C, Faivre J, Facy O and Bouvier AM: Incidence and survival in late liver metastases of colorectal cancer. J Gastroenterol Hepatol. 30:82–85. 2015. View Article : Google Scholar : PubMed/NCBI
3	Asano H, Kojima K, Ogino N, Fukano H, Ohara Y and Shinozuka N: Postoperative recurrence and risk factors of colorectal cancer perforation. Int J Colorectal Dis. 32:419–424. 2017. View Article : Google Scholar : PubMed/NCBI
4	Al Bandar MH and Kim NK: Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). Oncol Rep. 37:2553–2564. 2017. View Article : Google Scholar : PubMed/NCBI
5	Gires O: Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci. 68:4009–4022. 2011. View Article : Google Scholar : PubMed/NCBI
6	Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr: ASCO: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 24:5313–5327. 2006. View Article : Google Scholar : PubMed/NCBI
7	Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, et al: NCCN Clinical practice guidelines in oncology: Colon cancer. J Natl Compr Canc Netw. 7:778–831. 2009. View Article : Google Scholar : PubMed/NCBI
8	Rose J, Augestad KM and Cooper GS: Colorectal cancer surveillance: What's new and what's next. World J Gastroenterol. 20:1887–1897. 2014. View Article : Google Scholar : PubMed/NCBI
9	Labianca R, Nordlinger B, Beretta GD, Brouquet A and Cervantes A; ESMO Guidelines Working Group, : Primary colon cancer: ESMO Clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 21 (Suppl 5):v70–v77. 2010. View Article : Google Scholar : PubMed/NCBI
10	Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 23:2479–2516. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kawaguchi K and Morita M: ABC transporter subfamily D: Distinct differences in behavior between ABCD1-3 and ABCD4 in subcellular localization, function, and human disease. Biomed Res Int. 2016:67862452016. View Article : Google Scholar : PubMed/NCBI
12	Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1650–1654. 1992. View Article : Google Scholar : PubMed/NCBI
13	Holla VR, Wu H, Shi Q, Menter DG and DuBois RN: Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer. J Biol Chem. 286:30003–30009. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yu T, Zhang H and Qi H: Transcriptome profiling analysis reveals biomarkers in colon cancer samples of various differentiation. Oncol Lett. 16:48–54. 2018.PubMed/NCBI
15	Seborova K, Vaclavikova R, Soucek P, Elsnerova K, Bartakova A, Cernaj P, Bouda J, Rob L, Hruda M and Dvorak P: Association of ABC gene profiles with time to progression and resistance in ovarian cancer revealed by bioinformatics analyses. Cancer Med. 8:606–616. 2019. View Article : Google Scholar : PubMed/NCBI
16	Reams RR, Jones-Triche J, Chan OT, Hernandez BY, Soliman KF and Yates C: Immunohistological analysis of ABCD3 expression in Caucasian and African American prostate tumors. Biomed Res Int. 2015:1329812015. View Article : Google Scholar : PubMed/NCBI
17	Elsnerova K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, Gut I, Rob L, Skapa P, Hruda M, Bartakova A, Bouda J, et al: Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma. Oncol Rep. 35:2159–2170. 2016. View Article : Google Scholar : PubMed/NCBI
18	Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O, Holubec L, Treska V, et al: The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis. 27:187–196. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tsukamoto S, Ishikawa T, Iida S, Ishiguro M, Mogushi K, Mizushima H, Uetake H, Tanaka H and Sugihara K: Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 17:2444–2450. 2011. View Article : Google Scholar : PubMed/NCBI
20	Agesen TH, Berg M, Clancy T, Thiis-Evensen E, Cekaite L, Lind GE, Nesland JM, Bakka A, Mala T, Hauss HJ, et al: CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. Genes Immun. 12:653–662. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA and Domany E: Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancer. Proc Natl Acad Sci USA. 106:7131–7136. 2009. View Article : Google Scholar : PubMed/NCBI
22	Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, et al: Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
23	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
24	Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC and Müller M: pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 12:772011. View Article : Google Scholar : PubMed/NCBI
25	Trojani A, Pungolino E, Dal Molin A, Lodola M, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, et al: Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. PLoS One. 14:e02184442019. View Article : Google Scholar : PubMed/NCBI
26	Heimerl S, Bosserhoff AK, Langmann T, Ecker J and Schmitz G: Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells. Melanoma Res. 17:265–273. 2007. View Article : Google Scholar : PubMed/NCBI
27	Hendig D, Langmann T, Zarbock R, Schmitz G, Kleesiek K and Gotting C: Characterization of the ATP-binding cassette transporter gene expression profile in Y79: A retinoblastoma cell line. Mol Cell Biochem. 328:85–92. 2009. View Article : Google Scholar : PubMed/NCBI
28	Lauer C, Völkl A, Riedl S, Fahimi HD and Beier K: Impairment of peroxisomal biogenesis in human colon carcinoma. Carcinogenesis. 20:985–989. 1999. View Article : Google Scholar : PubMed/NCBI
29	Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, Funato T, Yokomizo A, Naito S, Imoto I, et al: Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 64:1403–1410. 2004. View Article : Google Scholar : PubMed/NCBI
30	Fletcher JI, Williams RT, Henderson MJ, Norris MD and Haber M: ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 26:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
31	Schuetz JD and Ishikawa T: ABC transporters and cancer. Preface. Adv Cancer Res. 125:xv–xvii. 2015. View Article : Google Scholar : PubMed/NCBI
32	Begicevic RR and Falasca M: ABC Transporters in cancer stem cells: Beyond chemoresistance. Int J Mol Sci. 18:E23622017. View Article : Google Scholar : PubMed/NCBI
33	Fung SW, Cheung PF, Yip CW, Ng LW, Cheung TT, Chong CC, Lee C, Lai PB, Chan AW, Tsao GS, et al: The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Lett. 457:98–109. 2019. View Article : Google Scholar : PubMed/NCBI
34	Li Y, Zhai Z, Li H, Wang X, Huang Y and Su X: Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells. Chem Biol Interact. 305:98–104. 2019. View Article : Google Scholar : PubMed/NCBI
35	Hou L, Zhang X, Jiao Y, Li Y, Zhao Y, Guan Y and Liu Z: ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer. Medicine (Baltimore). 98:e156982019. View Article : Google Scholar : PubMed/NCBI